“Reduction in Pruritus Across Indications in Phase 3 Trials of Topical Roflumilast in Patients As Young As 2 Years”. 2026. SKIN The Journal of Cutaneous Medicine 10 (2): s766. https://doi.org/10.25251/94s3pn30.